Improved brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs

摘要

Chemical according to GLN-1062 ** Formula ** for use as a medicament in the treatment of brain diseases associated with cognitive impairment, said treatment comprising transmucosal administration, selected between intranasal, sublingual or buccal administration of a therapeutically amount effective of a gluconate, saccharate or lactate salt of GLN 1062.